CD40 and mantle cell lymphoma: Lenalidomide exhibited antitumor activity in MCL cell lines by upregulating immune response genes, including CD40, CD58, and CD86, and inhibited IL6 production required for bone marrow-derived stromal cell activity [99, 101].